Vicore Pharma Holding AB

Kvartalsrapporter

Visar 1 grupper

  1. Kvartalsrapport Q1 2026

    ENSV
    →

    Financial Performance

    • Revenue for the first quarter of 2026 was SEK 0.6 million, compared to SEK 0.9 million in the same period of 2025.
    • Operating loss for the quarter amounted to SEK 123.8 million, compared to SEK 91.5 million in Q1 2025.
    • Loss for the period was SEK 108.6 million (Q1 2025: SEK 111.5 million).
    • Cash, cash equivalents, and short-term investments…

    Öppna rapport